AbbVie’s Puerto Rico pharmaceutical manufacturing facility lies within 70 miles of the capital, San Juan, in Barceloneta. The state-of-the-art plants are designed for modern drug finishing and biologics development, serving countries around the world from the newly invigorated sector of pharmaceutical manufacturing in Puerto Rico and globally.
AbbVie is committed to meeting and exceeding Puerto Rico pharmaceutical manufacturing guidelines and environmental policies.
AbbVie's Barceloneta location is comprised of two facilities situated centrally on the island's northern coastline, approximately 36 miles west of San Juan. One of the two plants at this location produces traditional small molecule drug product, including controlled drug production. The second plant is dedicated to biologics manufacturing of monoclonal antibody active pharmacutical ingredients (APIs). These facilities are part of several that support biologics, APIs and controlled drug production around the world.
AbbVie has a network of manufacturing facilities around the world to support your project and project needs. See AbbVie's other locations for additional manufacturing site information and technical expertise.
AbbVie’s Barceloneta operation is one of the world's most advanced biopharmaceutical facilities, contributing to the island's growing reputation as a biotech hub. The biologics facility is FDA-approved for commercial manufacturing, with 12,000 L bioreactors and more than 80 tanks and vessels. The drug product facility offers large-scale tablet and capsule processing, as well as potent and non-potent hot melt extrusion (HME).
AbbVie’s Barceloneta contract manufacturing expertise:
To discuss how these technologies can benefit your drug development program, contact AbbVie today.
AbbVie maintains a range regulatory standards and guidelines required by Puerto Rico pharmaceutical manufacturers.